View Older Stories
-
Evercore ISI Reinstates Becton Dickinson (BDX) at Outperform
-
BD launches CentroVena One central venous catheter insertion system
-
Becton Dickinson (BDX) Declares $1.05 Quarterly Dividend; 2.8% Yield
-
Goldman Sachs Resumes Becton Dickinson (BDX) at Neutral
-
BD executive Rick Byrd to retire after 25 years with company
-
BD receives CE mark for liver disease stent graft in Europe
-
Becton Dickinson (BDX)
-
Becton Dickinson (BDX) Launches AI-Enabled Medication Dispensing System to the European Market
-
Becton Dickinson (BDX) PT Lowered to $180 at Argus
-
BD receives FDA clearance for Surgiphor 1000mL wound irrigation system
-
BD launches new urine testing kit to reduce specimen contamination
-
Becton Dickinson (BDX) PT Lowered to $198 at Citi
-
BD launches $1.6 billion tender offers to buy back outstanding debt
-
Becton Dickinson (BDX) PT Lowered to $172 at RBC Capital
-
Becton Dickinson (BDX) PT Lowered to $170 at Piper Sandler
-
Barclays Resumes Becton Dickinson (BDX) at Overweight
-
Becton Dickinson (BDX) PT Lowered to $190 at Jefferies
-
RBC Capital Reiterates Sector Perform Rating on Becton Dickinson (BDX)
-
BD completes spin-off and merger of biosciences unit with Waters Corp
-
Becton Dickinson (BDX) Tops Q1 EPS by 10c ; Offers Guidance
-
Stifel: 'Disappointing 4Q25 electrophysiology performance is likely to pressure BSX shares today'
-
Citi Resumes Becton Dickinson (BDX) at Buy
-
BD and Envetec complete recycling pilot for medical plastic waste
-
BD declares $1.05 quarterly dividend, authorizes 10 million share buyback
-
Waters shareholders approve BD biosciences unit combination
-
BD launches AI-powered tool for flow cytometry research automation
-
BD and Ypsomed develop 5.5ml syringe for large-volume biologics
-
BD appoints Shawn Bevec as senior vice president of investor relations
-
BD invests $110 million in Nebraska prefillable syringe production
-
Becton Dickinson (BDX) PT Raised to $215 at Stifel: Many Avenues of Improvement
-
BD partners with Penn institute for immunotherapy research study
-
BD adds two diagnostic assays to European portfolio
-
Becton Dickinson (BDX) PT Raised to $220 at Jefferies
-
KeyBanc on Life Sciences Tools & Services: 'We Highlight Our Favored 2026 "Tools" Stocks'
-
Becton Dickinson (BDX) call put ratio 43 calls to 1 put with a focus on 11K contracts of March 220 calls
-
Increasing unusual option volume: BDX HPP DC BFB PCAR PVH IRBT FROG ODD FIVE
-
BD partners with ChemoGLO to expand hazardous drug testing services
-
BD launches three and four-laser cell analyzer configurations
-
Morgan Stanley Starts Waters Corp. (WAT) at Equalweight, 'High Quality Core Business but BDX Deal Bears Monitoring'
-
BD launches Surgiphor wound irrigation system in Europe
-
Becton Dickinson (BDX) Tops Q4 EPS by 4c, Misses on Revenue; Offers FY26 EPS Guidance
-
Becton Dickinson (BDX) Raises Quarterly Dividend 1% to $1.05; 2.4% Yield
-
BD launches at-home HPV testing solution for markets outside US
-
BD launches AI-enabled platform for healthcare device connectivity
-
Stifel Reiterates Buy Rating on Becton Dickinson (BDX) Following Disappointing Preliminary Q4 Sales Numbers
-
BD marks 65 years at Nebraska facility, invests over $50 million since 2020
-
RBC Capital Reiterates Sector Perform Rating on Becton Dickinson (BDX)
-
BD enrolls first patient in registry study for artery disease device
-
BD partners with Opentrons to automate single-cell analysis instruments
-
Needham: 'we believe that the Section 232 investigation creates a new overhang for the already beleaguered medical device sector'

